Elcam Medical has completed an acquisition designed to expand its product capabilities and offerings to customers. Elcam Medical, based in BarAm, Israel, acquired a majority interest in Injectech LLC, a privately held company based in Loveland, Colo.
Elcam Medical is an OEM supplier of fluid management, drug delivery and vital signs monitoring systems and devices. Injectech is an OEM provider of luer connectors, barbed fittings, check valves and custom injection molded components to the healthcare industry.
“We see great synergy between the two companies and their products,” said Ehud Raivitz, Elcam Medical’s CEO. “We are impressed with Injectech’s reputation among their customer base, especially their quality and responsiveness. Injectech also provides Elcam with a U.S.-based manufacturing operation.”
Terms of the transaction were not disclosed, and Injectech will operate as an independent entity.
Injectech offers complementary, non-competitive products to Elcam, the company said. In addition, they will be able to provide customers with rapid prototyping and fast turnaround times for their own products as well as being a local source for Elcam’s customers as needed. Conversely, Elcam, which is a provider of OEM stopcocks, is capable of doing high-volume runs that will benefit Injectech’s customers.
Dave Splett, vice president of Business Development and Larry Knipple, vice president of R&D will continue to manage Injectech’s operations. Lloyd Fishman, vice president of Business Development & Marketing for Elcam Medical, will serve as chairman of the board.
Elcam Medical is an OEM supplier of fluid management, drug delivery and vital signs monitoring systems and devices. Injectech is an OEM provider of luer connectors, barbed fittings, check valves and custom injection molded components to the healthcare industry.
“We see great synergy between the two companies and their products,” said Ehud Raivitz, Elcam Medical’s CEO. “We are impressed with Injectech’s reputation among their customer base, especially their quality and responsiveness. Injectech also provides Elcam with a U.S.-based manufacturing operation.”
Terms of the transaction were not disclosed, and Injectech will operate as an independent entity.
Injectech offers complementary, non-competitive products to Elcam, the company said. In addition, they will be able to provide customers with rapid prototyping and fast turnaround times for their own products as well as being a local source for Elcam’s customers as needed. Conversely, Elcam, which is a provider of OEM stopcocks, is capable of doing high-volume runs that will benefit Injectech’s customers.
Dave Splett, vice president of Business Development and Larry Knipple, vice president of R&D will continue to manage Injectech’s operations. Lloyd Fishman, vice president of Business Development & Marketing for Elcam Medical, will serve as chairman of the board.